Clinical trial
Wellbutrin XL, Major Depressive Disorder and Breast Cancer
NCT00234195 · Thomas Jefferson University, Other · Completed
Key facts
| NCT number | NCT00234195 |
|---|---|
| Title | Wellbutrin XL, Major Depressive Disorder and Breast Cancer |
| Official title | A Pilot Study of the Efficacy and Tolerability of Bupropion Extended Release (Wellbutrin XL) for the Treatment of Major Depressive Disorder in Women With Breast Cancer |
| Lead sponsor | Thomas Jefferson University, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Breast Cancer, Major Depressive Disorder |
| Intervention type | Drug |
| Interventions | bupropion extended release (Wellbutrin XL) |
| Enrollment | 25 |
| Start date | Sep 1, 2005 |
| Completion | Jan 1, 2007 |
| First posted | Oct 6, 2005 |
| Last update posted | Apr 17, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: